Image

A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy

Recruiting
18 years of age
Both
Phase 1

Powered by AI

Overview

The purpose of this study is to determine the safety and feasibility of administering the Tetanus Diptheria Vaccine (Td) or Polio Boost Immunization (IPOL) to patients with metastatic melanoma who are receiving immune checkpoint inhibitor (IO) therapy per standard of care. Subjects will have the vaccine at cycle 4 of IO therapy and will have research blood and tissue samples collected prior to starting IO therapy, at cycle 4 prior to vaccine administration, and at 12-17 days post vaccine.

Eligibility

Inclusion Criteria:

  1. Histologically confirmed advanced metastatic melanoma
  2. Male or female participants who are at least 18 years of age on the day of signing informed consent
  3. Participants must be planned or scheduled by their treating physician to receive PD-1 therapy or PD-1 plus anti CTLA-4 therapy as standard of care
  4. Participant (or legally acceptable representative if applicable) provides written informed consent for the trial
  5. Participant must have at least 1 lesion that is at least 8 mm in size and is cutaneous, subcutaneous, palpable, or amenable to ultrasound guided core biopsy. The lesion chosen for biopsy can also be a target lesion but does not have to be a target lesion
  6. Adequate organ function as defined below. Standard of care labs drawn within 45 days prior to consent may be used for the purposes of determining eligibility
    1. ANC >/= 1500/uL
    2. platelets >/=100,000/uL
    3. Hemoglobin >/= 9.0 g/dL

Exclusion Criteria:

  1. Uveal or mucosal melanoma
  2. Any women known to be pregnant or breastfeeding
  3. Any prior systemic therapy for metastatic melanoma (prior surgery is allowed)
  4. Known diagnosis of immunodeficiency or receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of prednisone or equivalent), or any other form of immunosuppressive therapy within 7 days prior to first research biopsy
  5. Patients with symptomatic CNS metastases and/or carcinomatous meningitis
    1. Patients with asymptomatic, stable CNS metastases are allowed provided that they are not on >10mg prednisone daily
  6. History of or active (non-infectious) pneumonitis that required steroids
  7. Active infection requiring systemic therapy
  8. Known history of Human Immunodeficiency Virus (HIV) infection
  9. Known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection. NOTE: no testing for Hepatitis B or Hepatitis C is required
  10. Known history of active TB (Bacillus Tuberculosis)
  11. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with subject's participation for the full duration of the study, or make it not in the best interest of the subject to participate, in the opinion of the treating physician
  12. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  13. History of allogenic tissue or solid organ transplant
  14. History of allergic reaction to IPOL or Td vaccine
  15. Receipt of Td vaccine within 30 days prior to starting IO therapy

Study details

Melanoma

NCT05077137

Duke University

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.